Wells Fargo & Company Forecasts Strong Price Appreciation for Bausch + Lomb (NYSE:BLCO) Stock

Bausch + Lomb (NYSE:BLCO) had its target price hoisted by equities researchers at Wells Fargo & Company from $17.00 to $18.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 0.28% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $19.00 price target on shares of Bausch + Lomb in a research note on Friday, January 9th. HC Wainwright increased their price target on shares of Bausch + Lomb from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. boosted their price objective on shares of Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. Finally, Citigroup boosted their price target on Bausch + Lomb from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bausch + Lomb currently has an average rating of “Hold” and an average price target of $18.00.

Bausch + Lomb Stock Performance

NYSE:BLCO opened at $17.95 on Thursday. The company has a quick ratio of 0.98, a current ratio of 1.55 and a debt-to-equity ratio of 0.77. The firm’s fifty day simple moving average is $17.06 and its 200 day simple moving average is $15.85. The stock has a market cap of $6.36 billion, a P/E ratio of -17.60, a price-to-earnings-growth ratio of 1.01 and a beta of 0.61. Bausch + Lomb has a twelve month low of $10.45 and a twelve month high of $18.12.

Bausch + Lomb (NYSE:BLCO) last posted its earnings results on Wednesday, February 18th. The company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.35 by ($0.03). Bausch + Lomb had a positive return on equity of 2.77% and a negative net margin of 7.06%.The company had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.38 billion. During the same period in the prior year, the business posted $0.25 earnings per share. The company’s revenue for the quarter was up 9.8% on a year-over-year basis. As a group, research analysts predict that Bausch + Lomb will post 0.74 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. lifted its position in Bausch + Lomb by 729.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after purchasing an additional 2,042 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Bausch + Lomb by 104.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after purchasing an additional 1,136 shares in the last quarter. FNY Investment Advisers LLC raised its position in shares of Bausch + Lomb by 93.8% during the 2nd quarter. FNY Investment Advisers LLC now owns 6,200 shares of the company’s stock valued at $80,000 after purchasing an additional 3,000 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after buying an additional 1,403 shares in the last quarter. Finally, Gruss & Co. LLC bought a new position in Bausch + Lomb in the 2nd quarter worth $130,000. 11.07% of the stock is currently owned by institutional investors.

Trending Headlines about Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Q4 revenue beat and operating leverage: Revenue of about $1.41B topped estimates and management highlighted strong revenue momentum and adjusted EBITDA expansion, supporting a constructive view on margin recovery and growth. Article Title
• Positive Sentiment: Analyst upgrade: Zacks moved BLCO to a Rank #2 (Buy), reflecting growing optimism on earnings prospects which can provide upside momentum. Article Title
• Positive Sentiment: Bullish research note: A Seeking Alpha review highlights 7% constant-currency Q4 revenue growth, 27% adjusted EBITDA growth, a product pipeline (contact lenses, dry-eye, premium IOLs) and management’s 5–7% annual revenue target through 2028 — supporting a multi-year growth story. Article Title
• Positive Sentiment: Price-target lift: Wells Fargo raised its price target to $18 (equal weight), a modest endorsement that reduces near-term downside risk. Article Title
• Neutral Sentiment: Earnings call/transcripts published — read for detail: Full Q4 earnings call transcripts are available (MSN / InsiderMonkey) for investors wanting management commentary on margins, guidance and product timing. Article Title
• Neutral Sentiment: Strategy/PR items: Management is promoting innovation (CEO highlights upcoming contact-lens innovations and has tied pay to AI literacy), which may support long-term positioning but is uncertain near-term catalyst. Article Title
• Negative Sentiment: EPS miss: Reported EPS of $0.32 missed consensus (~$0.35), which drove immediate volatility and raised short-term profitability concerns despite the revenue beat. Article Title
• Negative Sentiment: Analyst divergence and downside views: Bank of America reiterated a Sell citing structural/margin headwinds (PT $15); Stifel maintains Hold — mixed-to-negative analyst posture could cap upside. Article Title
• Negative Sentiment: Market reaction was mixed: some outlets reported an intra-session gap down tied to the earnings miss even as other coverage noted shares later edged higher — signalling investor uncertainty and possible continued volatility. Article Title

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.